Gregory Russotti net worth and biography

Gregory Russotti Biography and Net Worth

Insider of Century Therapeutics

Greg Russotti is Chief Technology and Manufacturing Officer at Century Therapeutics. Prior to joining Century, Dr. Russotti served as Vice President of Cell Therapy Development and Operations at Celgene. At Celgene, he guided chemistry, manufacturing and controls efforts for five different cell therapy products to clinical-stage development. Dr. Russotti was also a leader in establishing in-house clinical manufacturing at Celgene, and in building Celgene’s first commercial CAR T manufacturing facility. Earlier, he held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing. He received his BS and MS degrees in Chemical Engineering from Rensselaer Polytechnic Institute, and his PhD in Chemical and Biochemical Engineering from Rutgers University. Dr. Russotti has held a visiting professorship in Rutgers Biomedical Engineering department since 2008. He also serves as Industrial Executive Board Member of the Marcus Center for the Commercialization of Cell Therapies at Georgia Tech, and as an Executive Committee member of the National Science Foundation-funded Center for the Manufacturing of Advanced Therapeutics at Georgia Tech.

What is Gregory Russotti's net worth?: The estimated net worth of Gregory Russotti is at least $1.17 million as of March 12th, 2026. Mr. Russotti owns 515,427 shares of Century Therapeutics stock worth more than $1,172,596 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Russotti may own. Learn More about Gregory Russotti's net worth.
How do I contact Gregory Russotti?: The corporate mailing address for Mr. Russotti and other Century Therapeutics executives is , , . Century Therapeutics can also be reached via phone at 267-817-5790 and via email at [email protected]. Learn More on Gregory Russotti's contact information.
Has Gregory Russotti been buying or selling shares of Century Therapeutics?: Gregory Russotti has not been actively trading shares of Century Therapeutics during the last quarter. Most recently, Gregory Russotti sold 10,076 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $2.55, for a transaction totalling $25,693.80. Following the completion of the sale, the insider now directly owns 515,427 shares of the company's stock, valued at $1,314,338.85. Learn More on Gregory Russotti's trading history.
Who are Century Therapeutics' active insiders?: Century Therapeutics' insider roster includes Eli Casdin (Director), Osvaldo Flores (Pres), Brent Pfeiffenberger (CEO), and Gregory Russotti (Insider). Learn More on Century Therapeutics' active insiders.
Are insiders buying or selling shares of Century Therapeutics?: During the last year, Century Therapeutics insiders bought shares 3 times. They purchased a total of 145,060 shares worth more than $97,011.00. During the last year, insiders at the sold shares 18 times. They sold a total of 92,974 shares worth more than $80,629.43. The most recent insider tranaction occured on March, 12th when SVP Douglas Carr sold 7,043 shares worth more than $17,959.65. Insiders at Century Therapeutics own 4.4% of the company. Learn More about insider trades at Century Therapeutics.
Information on this page was last updated on 3/12/2026.

Gregory Russotti Insider Trading History at Century Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2026	Sell	10,076	$2.55	$25,693.80	515,427
3/9/2026	Sell	479	$2.54	$1,216.66	525,503
12/8/2025	Sell	526	$0.53	$278.78	390,982
9/8/2025	Sell	539	$0.50	$269.50	391,508
6/9/2025	Sell	526	$0.62	$326.12	392,047
3/10/2025	Sell	2,360	$0.61	$1,439.60	272,573
7/26/2024	Sell	586	$2.50	$1,465.00	274,933
7/23/2024	Sell	200	$2.50	$500.00	277,119
6/20/2024	Sell	5,000	$2.84	$14,200.00	277,319
6/5/2024	Sell	5,000	$3.00	$15,000.00	282,319
5/6/2024	Sell	5,000	$3.12	$15,600.00	292,319
4/22/2024	Sell	5,000	$3.10	$15,500.00	297,319

Gregory Russotti Buying and Selling Activity at Century Therapeutics

Century Therapeutics Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $2.28

$2.20

$2.30

50 Day Range

MA: $2.29

$1.75

$2.94

2 Week Range

Now: $2.28

$0.44

$3.04

Volume

505,619 shs

Average Volume

1,729,070 shs

Market Capitalization

$409.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66